Mayo Clinic报告针对单例CHCHD10基因突变ALS患者的实验性反义寡核苷酸疗法早期结果
Researchers report early results from therapy designed for a single patient with a rare genetic form of ALS
Mayo Clinic研究人员在Med期刊报告了一项针对单例CHCHD10基因突变型肌萎缩侧索硬化症(ALS)患者的实验性反义寡核苷酸(ASO)疗法的早期积极结果。该N-of-1研究显示,在接受6剂鞘内注射后,患者神经丝轻链水平下降高达50%,呼吸与认知功能保持稳定或轻微改善。该疗法目前仍处于实验研究阶段,旨在通过个体化精准医疗框架探索罕见遗传性疾病的靶向治疗潜力。
Mayo Clinic researchers report encouraging early results from an experimental therapy targeting the genetic cause of a rare form of amyotrophic lateral sclerosis, or ALS.
The single-patient study, published in Med, points to a broader possibility in precision medicine—using the genetic cause of a disease as a framework for testing highly targeted therapies, particularly for patients with rare conditions that have few treatment options.
"I didn't think I would see this kind of research in my lifetime—identifying a disease-causing mutation, developing an experimental therapy and delivering it to a patient," says Björn Oskarsson, M.D., a Mayo Clinic neurologist and senior author of the study. "It speaks to the power of science and how far genetically targeted treatments have come."
Targeting genetic ALS
That work builds on a long history of ALS genetics research at Mayo Clinic. In 2011, then-Mayo Clinic neurogeneticist Rosa Rademakers, Ph.D., and colleagues helped discover a mutation in the C9orf72 gene, now recognized as the most common inherited genetic cause of ALS.
Rademakers received the 2026 Breakthrough Prize in Life Sciences for her role in the discovery. Mayo researchers also developed early models that helped scientists investigate how the mutation contributes to ALS.
Since joining Mayo, Oskarsson has helped translate advances in ALS genetics into treatment research, contributing to the first approved treatment of genetic ALS.
ALS progressively damages motor neurons, the nerve cells that control voluntary movement. In this study, genetic testing identified a mutation in CHCHD10, a gene associated with a rare form of ALS. The mutation appears to make the CHCHD10 protein harmful to nerve cells and is linked to abnormal changes in TDP-43, a protein closely associated with ALS.
Mayo researchers collaborated with the nonprofit n-Lorem Foundation, which develops medicines based on antisense oligonucleotides, or ASOs, for people with ultrarare genetic diseases.
ASOs are short synthetic strands of genetic material designed to bind to RNA and reduce production of a protein that contributes to disease. The foundation developed and evaluated more than 320 ASOs targeting CHCHD10 before selecting a lead candidate based on specificity and early safety testing.
Early signs of treatment response
The study reports on the patient's first six doses of the experimental ASO, delivered through injections into the fluid surrounding the spinal cord. Treatment was well tolerated, and levels of neurofilament light—a blood biomarker of nerve-cell injury—declined by as much as 50%. Measures of breathing, cognition and physical function remained stable or showed modest improvement.
"The quick response in neurofilament light was very encouraging," Oskarsson says. In a progressive disease such as ALS, he adds, stabilization can be a meaningful observation.
The study also gives researchers a chance to look more closely at what is happening inside cells during the therapy. Using samples collected before and during the delivery of the ASOs, the team is studying changes in TDP-43 as well as mitochondrial function and gene activity. The goal is to understand how suppressing CHCHD10 may affect the disease process at a molecular level.
The therapy remains experimental research and is not standard clinical care. Oskarsson estimates that about 50% of ALS is genetic, but he notes that only a subset of those cases are currently suited to an antisense approach. Some genetic forms may require other strategies, including gene editing.
A framework for precision
The study is part of a broader effort through Mayo Clinic's N-of-1 Therapeutics Program to learn which elements of drug development, clinical evaluation and monitoring can be applied across individualized genetic therapies.
"Cases like this are how we get started," says Margot Cousin, Ph.D., director of the N-of-1 Therapeutics Program and lead author of the study. "They help us build the scientific, clinical, translational and regulatory framework to do this rigorously and equitably. As we learn how to scale these approaches, the impact could reach far beyond ultrarare disease."
Research in ultrarare diseases can help establish safety benchmarks, refine genetic-treatment platforms and clarify which disease mechanisms are most amenable to targeted therapy. Those lessons could ultimately inform new approaches to more common diseases.
Publication details
Margot A. Cousin et al, N-of-1 investigational study of a novel antisense oligonucleotide drug in CHCHD10-related ALS shows early signs of efficacy, Med (2026). DOI: 10.1016/j.medj.2026.101295
Journal information: Med
Who's behind this story?
Sadie Harley
BSc Life Sciences & Ecology. Microbiology lab background with pharmaceutical news experience in oil, gas, and renewable industries. Full profile →
Andrew Zinin
Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →
Citation: Researchers report early results from therapy designed for a single patient with a rare genetic form of ALS (2026, October 2) retrieved 2 October 2026 from https://medicalxpress.com/news/2026-10-early-results-therapy-patient-rare.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
来源:Medical Xpress · medicalxpress.com